GLP2-2G-XTEN: A Pharmaceutical Protein with Improved Serum Half-Life and Efficacy in a Rat Crohn's Disease Model

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Alters, Susan E ^a   McLaughlin, Bryant ^a   Spink, Benjamin ^a   Lachinyan, Tigran ^a   Wang, Chia wei ^a   Podust, Vladimir ^a   Schellenberger, Volker ^a   Stemmer, Willem P C ^a  

^a Amunix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GASTROINTESTINAL AGENT; GLP2 2G XTEN PEPTIDE; GLUCAGON LIKE PEPTIDE 2; GLUCAGON LIKE PEPTIDE 2 2G; HYBRID PROTEIN; LONG ACTING DRUG; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; FEMALE; HISTOPATHOLOGY; HYDROPHILICITY; IN VIVO STUDY; INTESTINE ULCER; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ORGAN WEIGHT; PROTEIN CONTENT; RAT; SMALL INTESTINE;

ANIMALS; CROHN DISEASE; DISEASE MODELS, ANIMAL; FEMALE; GLUCAGON-LIKE PEPTIDE 2; HUMANS; INDOMETHACIN; INTESTINE, SMALL; MACACA FASCICULARIS; MALE; MICE; RATS; RECOMBINANT FUSION PROTEINS;

MUS; RATTUS;

EID: 84870007801     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050630     Document Type: Article

References (32)

1. Drucker DJ, Erlich P, Asa SL, Brubaker PL, (1996) Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A 93: 7911-7916.
2. Brubaker PL, Izzo A, Hill M, Drucker DJ, (1997) Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol 272: E1050-1058.
3. Tsai CH, Hill M, Asa SL, Brubaker PL, Drucker DJ, (1997) Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol 273: E77-84.
4. Drucker DJ, DeForest L, Brubaker PL, (1997) Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2. Am J Physiol 273: G1252-1262.
5. Martin GR, Wallace LE, Hartmann B, Holst JJ, Demchyshyn L, et al. (2005) Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 288: G431-438.
6. Martin GR, Wallace LE, Sigalet DL, (2004) Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 286: G964-972.
7. Scott CE, Abdullah LH, Davis CW, (1998) Ca2+ and protein kinase C activation of mucin granule exocytosis in permeabilized SPOC1 cells. Am J Physiol 275: C285-292.
8. Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, et al. (2001) Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 120: 806-815.
9. Jeppesen PB, Sanguinetti EL, Buchman A, Howard L, Scolapio JS, et al. (2005) Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 54: 1224-1231.
10. Jeppesen PB, Lund P, Gottschalck IB, Nielsen HB, Holst JJ, et al. (2009) Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterol Res Pract 2009: 616054.
11. Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, et al. (2011) Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 60: 902-914.
12. Schmidt PT, Hartmann B, Bregenholt S, Hoist JJ, Claesson MH, (2000) Deficiency of the intestinal growth factor, glucagon-like peptide 2, in the colon of SCID mice with inflammatory bowel disease induced by transplantation of CD4+ T cells. Scand J Gastroenterol 35: 522-527.
13. Boushey RP, Yusta B, Drucker DJ, (1999) Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol 277: E937-947.
14. Alavi K, Schwartz MZ, Palazzo JP, Prasad R, (2000) Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. J Pediatr Surg 35: 847-851.
15. Drucker DJ, Yusta B, Boushey RP, DeForest L, Brubaker PL, (1999) Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol 276: G79-91.
16. L'Heureux MC, Brubaker PL, (2003) Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis. J Pharmacol Exp Ther 306: 347-354.
17. Sigalet DL, Wallace LE, Holst JJ, Martin GR, Kaji T, et al. (2007) Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 293: G211-221.
18. Yusta B, Huang L, Munroe D, Wolff G, Fantaske R, et al. (2000) Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 119: 744-755.
19. Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG, (2010) Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm Bowel Dis 16: 962-973.
20. Hartmann B, Harr MB, Jeppesen PB, Wojdemann M, Deacon CF, et al. (2000) In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab 85: 2884-2888.
21. Tavares W, Drucker DJ, Brubaker PL, (2000) Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. Am J Physiol Endocrinol Metab 278: E134-139.
22. Marier JF, Beliveau M, Mouksassi MS, Shaw P, Cyran J, et al. (2008) Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J Clin Pharmacol 48: 1289-1299.
23. Schellenberger V, Wang CW, Geething NC, Spink BJ, Campbell A, et al. (2009) A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol 27: 1186-1190.
24. Cleland JL, Geething NC, Moore JA, Rogers BC, Spink BJ, et al. (2012) A novel long-acting human growth hormone fusion protein (vrs-317): enhanced in vivo potency and half-life. J Pharm Sci.
25. Geething NC, To W, Spink BJ, Scholle MD, Wang CW, et al. (2010) Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose. PLoS One 5: e10175.
26. Lichtenstein GR, Yan S, Bala M, Hanauer S, (2004) Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 99: 91-96.
27. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, et al. (2005) Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353: 1912-1925.
28. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, et al. (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130: 323-333; quiz 591.
29. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, et al. (2007) Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 132: 1672-1683.
30. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, et al. (2007) Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357: 228-238.
31. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, et al. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337: 1029-1035.
32. Mahmood I, (2007) Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Adv Drug Deliv Rev 59: 1177-1192.